多西他赛联合低剂量顺铂治疗晚期高龄非小细胞肺癌的临床研究

郭仁宏; 唐桂棣; 潘良熹; 黄新恩; 冯继锋; 张全安

doi:10.3971/j.issn.1000-8578.3223

多西他赛联合低剂量顺铂治疗晚期高龄非小细胞肺癌的临床研究

1. 210009 南京,江苏省肿瘤医院内科;2. 江苏省南京市肿瘤医院内科

详细信息

中图分类号: R730. 53 ;R734. 2
计量
- 文章访问数: 2365
- HTML全文浏览量: 29
- PDF下载量: 893
出版历程
- 收稿日期: 2007-01-08
- 修回日期: 2007-03-04
- 刊出日期: 2008-02-04

Cl inical Observation of Docetaxel Combined with Low2dose Cisplatin for Treating Advanced Non2small Cell Lung Cancer in Elderly Patients

1. Department of Medical Oncolog y, J iangsu Tumor Hos pi tal, N anj ing 210009, China; 2. Depart2 ment of Medical Oncology, N anj ing Tumor Hos pi tal

摘要

摘要: 目的探讨多西他赛联合低剂量顺铂治疗晚期高龄非小细胞肺癌（NSCLC）的疗效及毒副反应。方法对31例晚期高龄NSCLC患者用多西他赛40mg／m^-2，静脉滴注，每周1次，连续2周；顺铂14mg／m^2，静脉滴注，每天1次，连用5次；以上化疗方案每4周重复1次，每例进行2周期化疗。结果全组31例，总有效率32．3％（10／31），其中PR10例，SD16例，PD5例，无CR病例，中位生存时间10．3个月。Ⅲ～Ⅳ度的中性粒细胞减少发生率为29．0％（9／31），非血液学毒性主要为疲劳乏力等（14／31，占45．2％）。结论周剂量多西他赛联合低剂量顺铂是治疗晚期高龄NSCLC较好的化疗方案
- 多西他赛 /
- 顺铂 /
- 非小细胞肺癌 /
- 药物治疗 /
- 老年人
Abstract: Objective 　To evaluated the efficacy and toxicity of Docetaxel combined with low2dose Cisplatin as alternative chemotherapy for elderly patient s with advanced non small cell lung cancer (NSCLC) . Methods 　Thirty2one patient s were enrolled in the study. Each was t reated as following : Docetaxel 40mg/ m2 infusion once per week for two weeks ; Cisplatin 14mg/ m2 / d infusion on day1～5. Af ter 2 con2 secutive t reatment course, each for 4 weeks, evaluation of the short2term efficacy and adverse effect s was carried out . Results 　The overall response rate was 32. 3 %(10/ 31) . CR0 (0 %), PR10 (32. 3 %), SD16 (51. 6 %), PD5 (16. 1 %), median OS was 10. 3 months. Hematologic toxicities, which were mild, in2 cluded grade Ⅲ～ Ⅳ neut ropenia in 29. 0 %(9/ 31) . The major non2hematologic toxicity was weakness (45. 2 %) . Conclusion 　Weekly Docetaxel combined with low2dose Cisplatin as alternative chemotherapy is encouraging for elderly patient s with advanced NSCLC.
- Docetaxel /
- Cisplatin /
- Non small cell lung cancer (NSCLC) /
- Drug therapy /
- Elderly